Shi-Ting Huang’s research while affiliated with Sichuan University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (28)


PRISMA selection flow diagram.
General clinicopathological features: (A) Age; (B) Gender; (C) Tumor Size; (D) T3 or T4 stage; (E) N3 or N4 stage; (F) Serum AFP.
Lymphatic permeation and vascular invasion: (A) Lymphatic permeation; (B) Vascular invasion.
Lymph nodes metastasis and liver metastasis: (A) Lymph nodes metastasis; (B) Lymph nodes metastasis (Remove significant heterogeneity): (C) Liver metastasis; (D) Liver metastasis (Remove significant heterogeneity).
Overall survival: (A) 3‐year survival; (B) 3‐year (Remove significant heterogeneity); (C) 5‐year survival.
Clinicopathological features of hepatoid adenocarcinoma and non‐hepatoid adenocarcinoma of the stomach: A systematic review and meta‐analysis
  • Literature Review
  • Full-text available

August 2024

·

27 Reads

Qi Ling

·

Han‐Lin Liu

·

Shi‐Ting Huang

·

[...]

·

Wei‐Han Zhang

Background Hepatoid adenocarcinoma of the stomach (HAS) is an extremely rare and unique malignant gastric tumor with a significantly worse prognosis than non‐hepatoid adenocarcinoma of the stomach (non‐HAS). The present study explored the clinicopathological features of HAS and non‐HAS patients to provide insights into HAS treatment strategies. Methods From December 26, 2023, we performed a comprehensive search of the PubMed, Web of Science, Cochrane Library, and Embase.com databases for relevant studies. Two authors independently screened the studies, evaluated their quality, extracted data, and performed the analyses. This study was registered with PROSPERO on January 2, 2024. Results Nine retrospective studies were included for analysis after screening 833 articles. A total of 350 and 924 patients were enrolled in the HAS and non‐HAS groups, respectively. While no significant differences were observed in age, sex, tumor size, T3 or T4 stage, and N2 or N3 stage between the two groups, the HAS group exhibited higher rates of lymph node metastasis (OR = 1.93, 95% CI: 1.19–3.13, p = 0.007), liver metastasis (OR = 3.45, 95% CI: 2.26–5.28, p < 0.001), and vascular invasion (OR = 2.76, 95% CI: 2.05–3.71, p < 0.001). Additionally, the HAS group had lower 3‐year survival rates (HR = 2.35, 95% CI: 1.70–3.25, p < 0.001) and 5‐year survival rates (HR = 3.63, 95% CI: 1.49–8.88, p = 0.005), but lower rates of lymphatic permeation (OR = 0.68, 95% CI: 0.47–0.99, p = 0.040). Conclusion Based on the current clinical evidence, patients with HAS present distinct clinicopathological features, greater invasiveness, and poorer prognosis than non‐HAS patients. Further research is warranted to develop optimal treatment strategies for HAS.

Download

Nomograms to predict the long-term prognosis for non-metastatic invasive lobular breast carcinoma: a population-based study

August 2024

·

16 Reads

Invasive lobular breast carcinoma (ILC) is one potential subset that “clinicopathologic features” can conflict with “long-term outcome” and the optimal management strategy is unknown in such discordant situations. The present study aims to predict the long-term, overall survival (OS) and cancer-specific survival (CSS) of ILC. The clinical information of patients with non-metastatic ILC was retrieved from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2020. A total of 31451 patients were enrolled and divided into the training cohort (n=22,017) and validation cohort (n=9434). The last follow-up was December, 31, 2020 and the median follow-up period was 99 months (1–203). Age, marriage, estrogen (ER) status, progesterone (PR) status, grade, tumor size, lymph node ratio (LNR) and combined summary (CS) stage were prognostic factors for both OS and CSS of ILC, whereas chemotherapy and radiation were independent protect factors for OS. The nomograms exhibited satisfactory discriminative ability. For the training and validation cohorts, the C-index of the OS nomogram was 0.765 (95% CI 0.762–0.768) and 0.757 (95% CI 0.747–0.767), and the C-index of the CSS nomogram were 0.812 (95% CI 0.804–0.820) and 0.813 (95% CI 0.799–0.827), respectively. Additionally, decision curve analysis (DCA) demonstrated that the nomograms had superior predictive performance than traditional American Joint Committee on Cancer (AJCC) TNM stage. The novel nomograms to predict long-term prognosis based on LNR are reliable tools to predict survival, which may assist clinicians in identifying high-risk patients and devising individual treatments for patients with ILC. Our findings should aid public health prevention strategies to reduce cancer burden. We provide two R/Shiny apps (https://ilc-survival2024.shinyapps.io/osnomogram/; https://ilc-survival2024.shinyapps.io/cssnomogram/) to visualize findings.


Overall Survival (OS) curves stratified by the American Joint Commission on Cancer (AJCC) 7th staging system for three groups. (a) total group stratified by stages I-IV; (b) chemoradiotherapy group stratified by stages I-IV; and (c) radiotherapy group stratified by stages I-IV. Corresponding group sizes and P‑values were presented. P < 0.05 was considered to indicate a statistically significant difference
Radiotherapy group overall survival (OS) curves stratified by (a) stage I and II-IV; (b) stage T0-T1 and T2-T4; (c) stage N0 and N1-3. Corresponding group sizes and P‑values are presented. P < 0.05 was considered to indicate a statistically significant difference
Annual survival rates and their comparisons of overall survival (OS) in different groups of patients
Year of surrogate endpoints in different groups stratified by TNM staging
Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area

July 2024

·

11 Reads

World Journal of Surgical Oncology

Purpose To address this evidence gap and validate short-term OS at less than 5 years as a reliable surrogate endpoint for 5-year OS. Methods We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on non-metastatic NPC patients diagnosed between 2010 and 2015. Patients were categorized into radiotherapy and chemoradiotherapy groups. Results This retrospective study examined 2,047 non-metastatic NPC patients. Among them, 217 received radiotherapy, and 1,830 received chemoradiotherapy. Our analysis results indicated that the 4-year OS may serve as a reliable surrogate endpoint for patients with AJCC clinical stage I (80 vs. 78%, P = 0.250), regardless of the treatment received. Specifically, in the radiotherapy group, patients with stage I, T0-T1, and N0 NPC showed similar OS rates at 4 and 5 years (83 vs. 82%, P = 1.000; 78 vs. 76%, P = 0.250; 78 vs. 77%, P = 0.500, respectively). Similarly, patients with stage II-IV, T2-T4, and N1-3 NPC showed no significant difference in OS rates between 3 and 5 years (57 vs. 51%, P = 0.063; 52 vs. 46%, P = 0.250; 54 vs. 46%, P = 0.125, respectively) in the radiotherapy group. In the chemoradiotherapy group, only the 3-year OS rate did not significantly differ from that at 5 years in stage I patients (79vs. 72%, P = 0.063). Conclusions Our study suggests that short-term surrogate endpoints may be valuable for evaluating 5-year OS outcomes in NPC patients in non-endemic areas.


Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis

December 2023

·

81 Reads

·

8 Citations

World Journal of Surgical Oncology

Background Following neoadjuvant chemotherapy, surgical resection is one of the most preferred treatment options for locally advanced gastric cancer patients. However, the optimal time interval between chemotherapy and surgery is unclear. This review aimed to identify the optimal time interval between neoadjuvant chemotherapy and surgery for advanced gastric cancer. Methods Beginning on November 12, 2022, we searched the PubMed, Cochrane Library, Web of Science databases, and Embase.com databases for relevant English-language research. Two authors independently screened the studies, assessed their quality, extracted the data, and analyzed the results. The primary goal was to investigate the relationship between the time interval to surgery (TTS) and long-term survival outcomes for patients. This study has been registered with PROSPERO (CRD42022365196). Results After an initial search of 4880 articles, the meta-analysis review ultimately included only five retrospective studies. Ultimately, this meta-analysis included 1171 patients, of which 411 patients had TTS of < 4 weeks, 507 patients had TTS of 4–6 weeks, and 253 patients had TTS of > 6 weeks. In survival analysis, patients with TTS of > 6 weeks had poorer overall survival outcomes than patients with TTS of 4–6 weeks ( HR = 1.34, 95% CI : 1.03–1.75, P = 0.03). No significant differences were found in terms of disease-free survival the groups. Conclusion Based on the current clinical evidence, patients with locally advanced gastric cancer may benefit better with a TTS of 4–6 weeks; however, this option still needs additional study.


Research trends of radiation induced temporal lobe injury in patients with nasopharyngeal carcinoma from 2000 to 2022: a bibliometric analysis

September 2023

·

27 Reads

·

4 Citations

Radiation Oncology

Background In patients with nasopharyngeal cancer (NPC), radiation-induced temporal lobe injury (TLI) is the most dreaded late-stage complication following radiation therapy (RT). We currently lack a definitive algorithmic administration for this entity. In the meantime, the pathogenesis of TLI and the mechanism-based interventions to prevent or treat this adverse effect remain unknown. To better answer the aforementioned questions, it is necessary to comprehend the intellectual foundations and prospective trends of this field through bibliometric analysis. Methods Articles were gathered from the Web of Science Core Collection (WoSCC) database between 2000 and 2022. CiteSpace was utilized to create a country/institutional co-authorship network, perform dual-map analysis, and find keywords with citation bursts. VOSviewer was used to build networks based on author co-authorship, journal citation, co-citation analysis of authors, references, and journals, and keyword co-occurrence. Results A total of 140 articles and reviews were included in the final analysis. The number of publications has steadily increased with some fluctuations over the years. The country and institution contributing most to this field are the China and Sun Yat-Sen University. Han Fei was the most prolific author, while Lee Awm was the most frequently cited. The analysis of co-occurrence revealed three clusters, including: “radiation-induced injury or necrosis in NPC,” “clinical studies on chemotherapy/radiotherapy complications and survival in recurrent NPC,” and “IMRT/chemotherapy outcomes and toxicities in head and neck cancer”). Most recent keyword bursts were “volume,” “temporal lobe injury,” “toxicities,” “model,” “survival,” “intensity modulated radiotherapy,” “induced brain injury,” “head and neck cancer,” and “temporal lobe.” Conclusion This study provides some insights of the major areas of interest in the field of radiation-induced TLI in patients with NPC by bibliometric analyses. This study assists scholars in locating collaborators and significant literature in this field, provides guidance for publishing journals, and identifies research hotspots. This analysis acknowledges significant contributions to the discipline and encourages the scientific community to conduct additional research.


The prognostic nutritional index represents a novel inflammation-nutrition-based prognostic factor for nasopharyngeal carcinoma

February 2023

·

36 Reads

·

8 Citations

Purpose This study explored the relationship between the prognostic nutritional index (PNI) and overall survival rate (OS) in patients with nasopharyngeal carcinoma (NPC), and established and validated an effective nomogram to predict clinical outcomes. Methods This study included 618 patients newly diagnosed with locoregionally advanced NPC. They were divided into training and validation cohorts at a ratio of 2:1 based on random numbers. The primary endpoint of this study was OS, progression-free survival (PFS) was the second endpoint. A nomogram was drawn from the results of multivariate analyses. Harrell’s concordance index (C-index), area under the receiver operator characteristic curve (AUC), and decision curve analysis (DCA) were used to evaluate the clinical usefulness and predictive ability of the nomogram and were compared to the current 8th edition of the International Union Against Cancer/American Joint Committee (UICC/AJCC) staging system. Results The PNI cutoff value was 48.1. Univariate analysis revealed that age (p < 0.001), T stage (p < 0.001), N stage (p = 0.036), tumor stage (p < 0.001), PNI (p = 0.001), lymphocyte-neutrophil ratio (NLR, p = 0.002), and lactate dehydrogenase (LDH, p = 0.009) were significantly associated with OS, age (p = 0.001), T-stage (p < 0.001), tumor stage (p < 0.001), N-stage (p = 0.011), PNI (p = 0.003), NLR (p = 0.051), and LDH (p = 0.03) were significantly associated with PFS. Multivariate analysis showed that age (p < 0.001), T-stage (p < 0.001), N-stage(p = 0.02), LDH (p = 0.032), and PNI (p = 0.006) were significantly associated with OS, age (p = 0.004), T-stage (<0.001), N-stage (<0.001), PNI (p = 0.022) were significantly associated with PFS. The C-index of the nomogram was 0.702 (95% confidence interval [CI]: 0.653–0.751). The Akaike information criterion (AIC) value of the nomogram for OS was 1142.538. The C-index of the TNM staging system was 0.647 (95% CI, 0.594–0.70) and the AIC was 1163.698. The C-index, DCA, and AUC of the nomogram demonstrated its clinical value and higher overall net benefit compared to the 8th edition of the TNM staging system. Conclusion The PNI represents a new inflammation-nutrition-based prognostic factor for patients with NPC. In the proposed nomogram, PNI and LDH were present, which led to a more accurate prognostic prediction than the current staging system for patients with NPC.


Patient selection flow. HCC Hepatocellular carcinoma; TACE Transcatheter arterial chemoembolization; ICC Intrahepatic cholangiocarcinoma; RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death
Best percentage change from baseline in sums of diameters of target lesions. A In the RT + PD1 group based on RECIST 1.1, B In the TACE plus sorafenib group based on RECIST 1.1, C In the RT + PD1 group based on mRECIST, D In the TACE plus sorafenib group based on mRECIST. RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death; TACE Transcatheter arterial chemoembolization; RECIST 1.1 Response Evaluation Criteria in Solid Tumors 1.1; mRECIST Modified Response Evaluation Criteria in Solid Tumors; CR Complete response; PR Partial response; SD Stable disease; PD Progressive disease
Kaplan–Meier analysis of overall and progression free survival. A PFS and B OS for all patients. HR Hazard ratio; RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death; TACE Transcatheter arterial chemoembolization; OS Overall survival; PFS Progression-free survival
Forest plot of PFS A and OS B in subgroups of patients. RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death; TACE Transcatheter arterial chemoembolization; OS Overall survival; PFS Progression-free survival; HBV Hepatitis B; BCLC Barcelona Clinic Liver Cancer; AFP Alpha-fetoprotein
Kaplan–Meier analysis of overall and progression free survival in patient subgroups. A OS among patients with BCLC-C; B OS among patients with MVI; RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death; TACE Transcatheter arterial chemoembolization; OS Overall survival; PFS Progression-free survival; BCLC-C Barcelona Clinic Liver Cancer C stage; MVI Macrovascular invasion; AFP Alpha-fetoprotein
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study

June 2022

·

41 Reads

·

11 Citations

Radiation Oncology

Abstract Background The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of radiotherapy (RT) plus monoclonal antibody against programmed cell death 1 (anti-PD1) versus TACE plus sorafenib for patients with advanced HCC. Methods Patients with advanced HCC who treated with RT plus anti-PD1 and TACE plus sorafenib were enrolled. Objective response rate (ORR), PFS, disease control rate (DCR) and OS were calculated to assess the antitumor response and the treatment-related adverse events to the safety. Results Between January 2018 to March 2021, 37 patients underwent RT plus anti-PD1 and 41 patients underwent TACE plus sorafenib. The baseline characteristics between the two groups were comparable. The ORR and DCR were significantly higher in the RT + PD1 group than the TACE plus sorafenib group according to RECIST 1.1 (54.05% vs. 12.20%, P


Survival among subgroups of patients with stage II nasopharyngeal carcinoma

April 2022

·

34 Reads

·

3 Citations

To assess survival between subgroups (T1N1, T2N0, and T2N1) of patients with stage II nasopharyngeal carcinoma (NPC). This retrospective cohort study evaluated pathologically confirmed stage II NPC patients from The Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016. The included patients were divided into three subgroups: T1N1, T2N0, and T2N1. Overall survival (OS) and cancer-specific survival (CSS) were assessed using the Kaplan–Meier method among the three subgroups. This study investigated 836 patients: 383 (45.8%) patients were in the T1N1 subgroup, 175 (20.9%) patients were in the T2N0 subgroup, and 278 (33.3%) patients were in the T2N1 subgroup. The 5-year OS (75.7%, 68.6%, and 75.7%) and CSS (85.3%, 83.4%, and 84.5%) were similar among the T1N1, T2N0, and T2N1 subgroups. Univariate and multivariate regression analyses revealed that the subgroup (T1N1, T2N0, and T2N1) of stage II NPC was not an independent prognostic factor for OS or CSS. Survival was comparable among subgroups (T1N1, T2N0, and T2N1) of stage II NPC patients. However, patients with T1N1, T2N0, and T2N1 stage disease who receive different treatments might have different prognoses.



Figure 4
Figures
Efficacy and Safety of Radiotherapy Plus Anti-PD1 Versus Transcatheter Arterial Chemoembolization Plus Sorafenib For Advanced Hepatocellular Carcinoma: a Real-World Study

December 2021

·

34 Reads

Background: The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of radiotherapy (RT) plus monoclonal antibody against programmed cell death 1 (anti-PD1) versus TACE plus sorafenib for patients with advanced HCC. Methods: Patients with advanced HCC who treated with RT plus anti-PD1 and TACE plus sorafenib were enrolled. Objective response rate (ORR), PFS, disease control rate (DCR) and OS were calculated to assess the antitumor response and the treatment-related adverse events to the safety. Results: Between January 2018 to March 2021, 37 patients underwent RT plus anti-PD1 and 41 patients underwent TACE plus sorafenib. The baseline characteristics between the two groups were comparable. The ORR and DCR were significantly higher in the RT+PD1 group than the TACE plus sorafenib group according to RECIST 1.1 (54.05% vs 12.20%, P < 0.001; 70.27% vs 46.37%, P = 0.041; respectively) and according to mRECIST (56.76% vs 31.71%, P = 0.039; 70.27% vs 46.37%, P = 0.041; respectively). RT plus anti-PD1 provided significantly better PFS (HR, 0.51; 95% CI 0.30-0.86; p=0.017) than TACE plus sorafenib. Moreover, patients with RT plus anti-PD1 had significantly higher 3-, 6-, and 9-month OS rates than those with TACE plus sorafenib(97.3% vs 92.30%, P < 0.001; 91.89% vs 68.60%, P < 0.001; 75.5% vs 60.60%, P < 0.001; respectively). The median OS was more favorable 17.4 months for the RT+PD1 group and 11.9 months for the TACE plus sorafenib group. No treatment-related death was observed. Grade 3 or more treatment-related adverse events (TRAEs) occurred significantly less in patients in the RT+PD1 group than the TACE plus sorafenib group (29.7% vs 75.6%, p < 0.001), and all TRAEs were manageable. Conclusions: In this real-world study, RT plus anti-PD1 showed significantly promising efficacy and manageable safety than TACE plus sorafenib in patients with advanced HCC. Toxicities were manageable, with no unexpected safety signals. The study provides evidence on a new therapeutic method in the treatment of advanced HCC.


Citations (23)


... On the other hand, larger studies have been unable to support this claim. Several hypotheses have been proposed to explain this divergence [27]. One suggestion is that pCR might only reflect the primary tumor's response to the treatment, whereas the impact on micro-metastatic disease could be more significant. ...

Reference:

Complete Pathological Response in a Young Patient with Poorly Differentiated Gastric Adenocarcinoma Following Flot Neoadjuvant Chemotherapy: A Case Report
Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis

World Journal of Surgical Oncology

... 4,5 Radiation-induced brain injury emerges as a significant and severe complication following radiotherapy for individuals with primary, secondary, or intracranial tumors. 6,7 The condition can lead to brain tissue necrosis, edema, demyelination, and subsequent cognitive and memory impairment. 8 The precise causes of radiation-induced brain injury remain elusive, leading to a paucity of effective and specialized treatment options. ...

Research trends of radiation induced temporal lobe injury in patients with nasopharyngeal carcinoma from 2000 to 2022: a bibliometric analysis

Radiation Oncology

... In contrast, Buzey et al. introduced the PNI, derived from serum albumin concentration and peripheral blood lymphocyte count [32]. Lymphocytes play a crucial role in the immune response, inhibiting tumor cell proliferation and metastasis [33]. ...

The prognostic nutritional index represents a novel inflammation-nutrition-based prognostic factor for nasopharyngeal carcinoma

... We hope to make aware of the important role of RT and provide some references for the physician in making decision of HCC treatment. The combination of RT and anti-PD1 has been effective in patients with advanced HCC, with a median survival of 20.9 months without an increase in treatment side effects (31)(32)(33). RT has the ability to transform the tumor microenvironment, characterized by low immunogenicity and inadequate immune cell infiltration, into one with a robust immunological response (34, 35). The immune system activated by RT can also be used in conjunction with immune checkpoint inhibitors (ICIs) to disrupt immune escape and produce a more potent antitumor effect. ...

Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study

Radiation Oncology

... Our results indicated that there was no statistical difference in the Kaplan-Meier analysis for the two sub-stages after treatment. Previous research findings also indicated that T1-2N1M0 and T2N0M0 stages were not identified as prognostic factors for overall survival regardless of treatment (25). ...

Survival among subgroups of patients with stage II nasopharyngeal carcinoma

... Most clinical trials and observational studies used the median age at diagnosis as the cutoff value to divide patients into 2 groups. [12][13][14][15][16] Several studies reported that age at diagnosis was not an independent prognostic factor. Nevertheless, some suggested that median age is an independent prognostic factor. ...

Efficacy of Chemotherapy in Survival of Stage I Nasopharyngeal Carcinoma

... The main changes to T staging in the Eighth Edition are as follows: medial pterygoid, lateral pterygoid, or prevertebral muscle involvement was included in T2, cervical vertebral invasion was included in T3, and the ambiguous terms infratemporal fossa/masticator space invasion was removed and replaced with extensive soft tissue invasion (soft tissue outside the lateral pterygoid muscle and parotid gland) in T4. 4 Regarding N staging changes, stages N3a and N3b in the Seventh Edition were merged into a single stage, N3, and the N3 criterion was changed to "below the caudal border of cricoid cartilage." 4 However, some studies have expressed support for these changes, [5][6][7][8][9] while others have not. [10][11][12][13][14] Many studies have shown that N staging is reasonable [5][6][7][8][9] while T staging needs further improvement. ...

Maximal lymph nodal diameter on N stage of nasopharyngeal carcinoma

Medicine

... N staging is a key factor for predicting distant metastasis, and about 70%~85% of NPC patients have regional lymph node metastasis. Laryngeal lymph nodes are risk factors for distant metastasis, which may cause radiotherapy resistance and then distant metastasis due to heavy tumor load and cell hypoxia (19) . As a statistical model for accurate prediction of clinical events, nomograph model has been used to guide treatment protocols for cancer patients (20)(21) . ...

Retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma

... In terms of the evaluation of xerostomia, this study used the RTOG scoring standard to evaluate the generation and grading of clinical dry mouth. 19,20 During the course of our planned radiotherapy, no patient had grade 4 xerostomia, and it was found that the grade of acute irradiation-induced xerostomia gradually increased with increasing interval time during the course of radiotherapy, especially regarding grade 2 irradiationinduced xerostomia ( Figure 5). There was a significant negative correlation between NIC and xerostomia. ...

Dosimetry of Submandibular Glands on Xerostomia for Nasopharyngeal Carcinoma

... Recent studies have indicated that EBV DNA levels in plasma, serum, or peripheral blood cells serve as a valuable prognostic marker for NPC patients (10). However, routine EBV DNA testing has only recently been implemented in our clinic. ...

Neutrophil-to-lymphocyte ratio predicts the prognosis of stage II nasopharyngeal carcinoma